ドイツのIBD (炎症性腸疾患) 市場：2019-2025年
Germany Inflammatory Bowel Disease (IBD) Market 2019-2025
|ドイツのIBD (炎症性腸疾患) 市場：2019-2025年|
発行: Orion Market Research Pvt Ltd
ドイツのIBD (炎症性腸疾患) の市場は予測期間中、約5.4％のCAGRで成長すると予測されています。患者数の増加が同市場の成長を推進しています。2018年におけるクローン病の有病率は10万人あたり322人と推定されています。また、高品質の医療サービスに対する需要の増加も市場成長を後押しするもう1つの要因です。国内の医療費も過去数年間で大幅に増加しており、今後も同様の傾向が見込まれます。このことから、今後IBDなどの炎症性疾患へのR&D投資が拡大すると見込まれており、予測期間中の市場開発の機会を創出すると予測されています。
当レポートでは、ドイツのIBD (炎症性腸疾患) の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、関連法規制、市場規模の推移・予測、疾患区分・治療法など各種区分別の内訳、競合環境、企業シェア、主要企業のプロファイルなどをまとめています。
Germany Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn's Disease), By Treatment Type (Surgery and Anti- Inflammatory Drug Administration) and Forecast 2019-2025
Germany IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.4% during the forecast period. The growing IBD patient population in the region is one of the major driving forces for the growth of the market in the country. According to the national institutes of health, the prevalence of Crohn's disease in Germany was estimated to be 322 per 100,000 in Germany in 2018. Moreover, the growing demand for quality healthcare services in the region is another factor boosting the germany IBD market. The healthcare expenditure in Germany has also been increasing significantly in the past years. A similar trend is expected to be followed in the future. This is expected to be one of the key reasons which are estimated to increase the inflow of R&D funds in inflammatory diseases such as IBD in the future. This is projected to create opportunities for the development of the market over the forecast period.
Germany IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis. For Crohn's and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
The companies which are contributing to the growth of the Germany IBD therapeutics market include AbbVie Inc., Allergan, PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc., Pharmacosmos A/S, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
The market study of Germany IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The Report Covers: